Section Arrow
GMAB.NASDAQ
- Genmab A/S ADS
Quotes are at least 15-min delayed:2026/06/06 03:38 EDT
Regular Hours
Last
 25.15
+0.42 (+1.70%)
Day High 
25.289 
Prev. Close
24.73 
1-M High
28.2799 
Volume 
2.09M 
Bid
24.75
Ask
25.42
Day Low
24.69 
Open
24.73 
1-M Low
23.62 
Market Cap 
15.18B 
Currency 美元 
P/E 19.13 
%Yield -- 
10-SMA 25.88 
20-SMA 26.24 
50-SMA 26.91 
52-W High 35.43 
52-W Low 20.225 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.32/11.38
Enterprise Value
20.32B
Balance Sheet
Book Value Per Share
9.26
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
3.72B
Operating Revenue Per Share
3.93
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
BCDABioCardia Inc.1.03+0.111+12.08%-- 
BGMSBio Green Med Solution Inc1.5+0.44+41.51%0.3PE
CMNDClearmind Medicine Inc.3.98+1.07+36.77%-- 
ADTXAditxt Inc.0.0621-0.0149-19.35%-- 
RXRXRecursion Pharmaceuticals3.315-0.485-12.76%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.